{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T12:03:47Z","timestamp":1753877027687,"version":"3.41.2"},"reference-count":39,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2019,4,15]],"date-time":"2019-04-15T00:00:00Z","timestamp":1555286400000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1093\/infdis\/jiz160","type":"journal-article","created":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T22:00:16Z","timestamp":1554328816000},"source":"Crossref","is-referenced-by-count":11,"title":["Economic-Burden Trajectories in Commercially Insured US Infants With Respiratory Syncytial Virus Infection"],"prefix":"10.1093","author":[{"given":"Viktor V","family":"Chirikov","sequence":"first","affiliation":[{"name":"Real World Evidence, Pharmerit International, Bethesda, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric A F","family":"Sim\u00f5es","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Colorado School of Medicine"},{"name":"Department of Epidemiology, Center for Global Health, Colorado School of Public Health"},{"name":"Section of Infectious Disease, Children\u2019s Hospital Colorado, Aurora"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Kuznik","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research, Regeneron, Tarrytown, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youngmin","family":"Kwon","sequence":"additional","affiliation":[{"name":"Real World Evidence, Pharmerit International, Bethesda, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Botteman","sequence":"additional","affiliation":[{"name":"Real World Evidence, Pharmerit International, Bethesda, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,4,15]]},"reference":[{"key":"2019051709394731700_CIT0001","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ccm.2016.11.010","article-title":"Respiratory syncytial virus infection: an illness for all ages","volume":"38","author":"Walsh","year":"2017","journal-title":"Clin Chest Med"},{"key":"2019051709394731700_CIT0002","first-page":"39","article-title":"Clinical and epidemiologic features of respiratory syncytial virus","volume":"372","author":"Hall","year":"2013","journal-title":"Curr Top Microbiol Immunol"},{"key":"2019051709394731700_CIT0003","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3111\/13696998.2011.578188","article-title":"Association of RSV lower respiratory tract infection and subsequent healthcare use and costs: a Medicaid claims analysis in early-preterm, late-preterm, and full-term infants","volume":"14","author":"Shi","year":"2011","journal-title":"J Med Econ"},{"key":"2019051709394731700_CIT0004","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1185\/03007990903290894","article-title":"Total healthcare costs in the US for preterm infants with respiratory syncytial virus lower respiratory infection in the first year of life requiring medical attention","volume":"25","author":"Stewart","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"2019051709394731700_CIT0005","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/jp.2016.113","article-title":"Respiratory syncytial virus hospitalization outcomes and costs of full-term and preterm infants","volume":"36","author":"McLaurin","year":"2016","journal-title":"J Perinatol"},{"key":"2019051709394731700_CIT0006","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/ppul.23570","article-title":"Respiratory syncytial virus hospitalization and mortality: systematic review and meta-analysis","volume":"52","author":"Stein","year":"2017","journal-title":"Pediatr Pulmonol"},{"key":"2019051709394731700_CIT0007","doi-asserted-by":"crossref","first-page":"e0166226","DOI":"10.1371\/journal.pone.0166226","article-title":"Effects of chronologic age and young child exposure on respiratory syncytial virus disease among US preterm infants born at 32 to 35 weeks gestation","volume":"11","author":"Sim\u00f5es","year":"2016","journal-title":"PLoS One"},{"key":"2019051709394731700_CIT0008","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/j.1399-3038.2005.00298.x","article-title":"Hospitalization for RSV bronchiolitis before 12 months of age and subsequent asthma, atopy and wheeze: a longitudinal birth cohort study","volume":"16","author":"Henderson","year":"2005","journal-title":"Pediatr Allergy Immunol"},{"key":"2019051709394731700_CIT0009","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s40121-017-0167-9","article-title":"Chronologic age at hospitalization for respiratory syncytial virus among preterm and term infants in the United States","volume":"6","author":"Parikh","year":"2017","journal-title":"Infect Dis Ther"},{"key":"2019051709394731700_CIT0010","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/ppul.21244","article-title":"Healthcare costs within a year of respiratory syncytial virus among Medicaid infants","volume":"45","author":"Palmer","year":"2010","journal-title":"Pediatr Pulmonol"},{"key":"2019051709394731700_CIT0011","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1136\/thx.2009.121582","article-title":"Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life","volume":"65","author":"Sigurs","year":"2010","journal-title":"Thorax"},{"key":"2019051709394731700_CIT0012","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s40121-017-0151-4","article-title":"The burden and long-term respiratory morbidity associated with respiratory syncytial virus infection in early childhood","volume":"6","author":"Fauroux","year":"2017","journal-title":"Infect Dis Ther"},{"volume-title":"The Truven Health MarketScan Databases for Health Services Researchers. Overview of MarketScan claims data","year":"2019","author":"Truven Health Analytics","key":"2019051709394731700_CIT0013"},{"key":"2019051709394731700_CIT0014","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1001\/jamapediatrics.2013.2636","article-title":"Appropriateness of age thresholds for respiratory syncytial virus immunoprophylaxis in moderate-preterm infants: a cohort study","volume":"167","author":"Winterstein","year":"2013","journal-title":"JAMA Pediatr"},{"key":"2019051709394731700_CIT0015","first-page":"230","article-title":"Respiratory syncytial virus activity - United States, July 2008\u2013December 2009","volume":"59","author":"Centers for Disease Control Prevention","year":"2010","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2019051709394731700_CIT0016","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/pds.3407","article-title":"Validation of an algorithm to estimate gestational age in electronic health plan databases","volume":"22","author":"Li","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2019051709394731700_CIT0017","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1186\/1471-2431-14-261","article-title":"Partial palivizumab prophylaxis and increased risk of hospitalization due to respiratory syncytial virus in a Medicaid population: a retrospective cohort analysis","volume":"14","author":"Krilov","year":"2014","journal-title":"BMC Pediatr"},{"key":"2019051709394731700_CIT0018","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/00001648-200009000-00012","article-title":"Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men","volume":"11","author":"Hern\u00e1n","year":"2000","journal-title":"Epidemiology"},{"key":"2019051709394731700_CIT0019","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1080\/00273171.2011.540480","article-title":"A tutorial and case study in propensity score analysis: an application to estimating the effect of in-hospital smoking cessation counseling on mortality","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"key":"2019051709394731700_CIT0020","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/rssb.12027","article-title":"Covariate balancing propensity score","volume":"76","author":"Imai","year":"2014","journal-title":"J R Stat Soc Series B Stat Methodol"},{"key":"2019051709394731700_CIT0021","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1093\/aje\/kwu181","article-title":"The role of prediction modeling in propensity score estimation: an evaluation of logistic regression, bCART, and the covariate-balancing propensity score","volume":"180","author":"Wyss","year":"2014","journal-title":"Am J Epidemiol"},{"key":"2019051709394731700_CIT0022","doi-asserted-by":"crossref","first-page":"6079","DOI":"10.1002\/cncr.27638","article-title":"Comparative effectiveness and cost of adding rituximab to first-line chemotherapy for elderly patients diagnosed with diffuse large B-cell lymphoma","volume":"118","author":"Griffiths","year":"2012","journal-title":"Cancer"},{"key":"2019051709394731700_CIT0023","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.jval.2012.03.1388","article-title":"Inverse probability weighted least squares regression in the analysis of time-censored cost data: an evaluation of the approach using SEER-Medicare","volume":"15","author":"Griffiths","year":"2012","journal-title":"Value Health"},{"key":"2019051709394731700_CIT0024","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/1475-6773.12090","article-title":"Generalizing observational study results: applying propensity score methods to complex surveys","volume":"49","author":"Dugoff","year":"2014","journal-title":"Health Serv Res"},{"key":"2019051709394731700_CIT0025","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.2105\/AJPH.2011.300398","article-title":"Use of design effects and sample weights in complex health survey data: a review of published articles using data from 3 commonly used adolescent health surveys","volume":"102","author":"Bell","year":"2012","journal-title":"Am J Public Health"},{"key":"2019051709394731700_CIT0026","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1093\/cid\/cix432","article-title":"Identifying gaps in respiratory syncytial virus disease epidemiology in the United States prior to the introduction of vaccines","volume":"65","author":"Kim","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2019051709394731700_CIT0027","first-page":"S0264-410X(17)31364-6","article-title":"Respiratory syncytial virus vaccine research and development: World Health Organization technological roadmap and preferred product characteristics","author":"Vekemans","year":"2018","journal-title":"Vaccine"},{"key":"2019051709394731700_CIT0028","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2213-2600(17)30303-X","article-title":"Determining the outcomes of interventions to prevent respiratory syncytial virus disease in children: what to measure?","volume":"6","author":"Karron","year":"2018","journal-title":"Lancet Respir Med"},{"unstructured":"Sim\u00f5es\n              EA\n            , ChirikovVV, KwonY, BottemanMF, KuznikA. Long-term assessment of healthcare utilization five years after respiratory syncytial virus infection in US infants. Presented at: 11th International RSV Symposium, Asheville, North Carolina, 31 October \u20134 November 2018.","key":"2019051709394731700_CIT0029"},{"key":"2019051709394731700_CIT0030","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1097\/INF.0000000000000813","article-title":"Clinical endpoints for respiratory syncytial virus prophylaxis trials in infants and children in high-income and middle-income countries","volume":"34","author":"Sim\u00f5es","year":"2015","journal-title":"Pediatr Infect Dis J"},{"key":"2019051709394731700_CIT0031","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1164\/rccm.201609-1812OC","article-title":"Palivizumab prophylaxis in preterm infants and subsequent recurrent wheezing. Six-year follow-up study","volume":"196","author":"Mochizuki","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2019051709394731700_CIT0032","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S2213-2600(18)30055-9","article-title":"Respiratory syncytial virus prevention and asthma in healthy preterm infants: a randomised controlled trial","volume":"6","author":"Scheltema","year":"2018","journal-title":"Lancet Respir Med"},{"key":"2019051709394731700_CIT0033","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1016\/j.vaccine.2016.03.109","article-title":"Advances in RSV vaccine research and development - a global agenda","volume":"34","author":"Higgins","year":"2016","journal-title":"Vaccine"},{"key":"2019051709394731700_CIT0034","first-page":"1","article-title":"Assessing variation in the cost of palivizumab for respiratory syncytial virus prevention in preterm infants","author":"Shahabi","year":"2017","journal-title":"Pharmacoecon Open"},{"key":"2019051709394731700_CIT0035","doi-asserted-by":"crossref","first-page":"S177","DOI":"10.1093\/infdis\/jit512","article-title":"Progress and challenges in RSV prophylaxis and vaccine development","volume":"208","author":"Haynes","year":"2013","journal-title":"J Infect Dis"},{"key":"2019051709394731700_CIT0036","doi-asserted-by":"crossref","first-page":"ofy031","DOI":"10.1093\/ofid\/ofy031","article-title":"Palivizumab prophylaxis for respiratory syncytial virus: examining the evidence around value","volume":"5","author":"Olchanski","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"2019051709394731700_CIT0037","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1055\/s-0037-1606352","article-title":"The 2014\u20132015 national impact of the 2014 American Academy of Pediatrics guidance for respiratory syncytial virus immunoprophylaxis on preterm infants born in the United States","volume":"35","author":"Kong","year":"2018","journal-title":"Am J Perinatol"},{"key":"2019051709394731700_CIT0038","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s00431-017-3046-1","article-title":"Cost-effectiveness of rule-based immunoprophylaxis against respiratory syncytial virus infections in preterm infants","volume":"177","author":"Blanken","year":"2018","journal-title":"Eur J Pediatr"},{"key":"2019051709394731700_CIT0039","doi-asserted-by":"crossref","first-page":"e367","DOI":"10.1016\/S2468-2667(17)30103-2","article-title":"Burden of paediatric respiratory syncytial virus disease and potential effect of different immunisation strategies: a modelling and cost-effectiveness analysis for England","volume":"2","author":"Cromer","year":"2017","journal-title":"Lancet Public Health"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiz160\/28667543\/jiz160.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"}],"deposited":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T13:40:03Z","timestamp":1558100403000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/advance-article\/doi\/10.1093\/infdis\/jiz160\/5459340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,15]]},"references-count":39,"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiz160","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"type":"print","value":"0022-1899"},{"type":"electronic","value":"1537-6613"}],"subject":[],"published":{"date-parts":[[2019,4,15]]},"article-number":"jiz160"}}